MilliporeSigma has opened its first BioReliance End-to-End Biodevelopment Center in the Asia Pacific (APAC) region. Located in Shanghai, China, the center will provide a full range of process development capabilities and services, including cell line development, upstream and downstream process development and non-GMP clinical production. “Our new BioReliance End-to-End Biodevelopment Center will host small-scale drug manufacturers working on early-phase clinical trials,” said Udi...